Clinical Data

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Rhythm’s obesity pill trial hits primary goal, sending stock up

A phase 2 trial of the biotech’s next-generation oral candidate hit its primary endpoint, sending the stock up 26%.
Nick Paul Taylor Jul 9, 2025 10:21am
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am
Graphic image of an arrow nailing the bullseye of a target

Cogent hits primary endpoint, building case for Blueprint rival

Jul 7, 2025 9:16am
An arrow incrementally going up stairs before pointing straight up Blue background

Biokin, having landed BMS deal, posts ph. 3 bispecific ADC win

Jul 2, 2025 9:53am
long shot miss basketball hoop fail shoot

Organon axes 'biggest potential opportunity' after trial fail

Jul 2, 2025 8:43am
Close up shot of the target from a dart game

Amgen, Zai say stomach cancer candidate hits phase 3 mark

Jun 30, 2025 10:36am